Vyvanse Cost in Montana 2026: Prices, Insurance, Savings Programs

What Vyvanse Actually Costs at Montana Pharmacies

The sticker price and what you pay are two different numbers. Takeda's wholesale acquisition cost for brand-name Vyvanse is $390 per month across all dosage strengths [1]. That figure rarely reflects what a patient hands over at the counter.

In 2026, the average cash-pay price for a 30-day supply of lisdexamfetamine at Montana retail pharmacies hovers around $35 per month when patients use manufacturer coupons or pharmacy discount platforms [2]. Prices vary by pharmacy and by city. A Costco in Billings, a Walmart in Missoula, and an independent pharmacy in Great Falls will each post a different number. Checking multiple sources before filling is worth the five minutes it takes.

The FDA approved generic lisdexamfetamine dimesylate in August 2023, and multiple generic manufacturers now supply the market [3]. Generic availability drove cash prices down significantly from the $300+ range that patients faced for brand-name Vyvanse before 2023. Montana pharmacies stock generics from manufacturers including Teva, Amneal, and Alvogen. If your pharmacy quotes you a price above $80 for a 30-day generic supply, ask them to run a discount card or check a competing pharmacy's price.

Montana Medicaid and Vyvanse Coverage

Montana Medicaid does not cover Vyvanse or generic lisdexamfetamine on its preferred drug list as of 2026 [4]. This applies to both traditional Medicaid and the Montana HELP Act expansion population.

Patients enrolled in Montana Medicaid who need treatment for ADHD are typically directed toward covered alternatives. The Montana Medicaid preferred drug list includes generic mixed amphetamine salts (Adderall generics), generic methylphenidate formulations, and certain extended-release stimulant preparations [4]. A prescriber can submit a prior authorization request arguing medical necessity for lisdexamfetamine if a patient has tried and failed preferred agents. Approval is not guaranteed. The Montana Department of Public Health and Human Services requires documentation of therapeutic failure on at least one preferred stimulant before considering non-preferred options.

Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "Lisdexamfetamine's prodrug mechanism provides a smoother pharmacokinetic profile with lower abuse liability compared to immediate-release amphetamine formulations, which can be clinically meaningful for specific patient populations" [5]. That clinical distinction may support a prior authorization argument if a patient's history demonstrates problems with preferred agents.

Private Insurance Coverage in Montana

Commercial insurance plans in Montana vary widely in how they handle lisdexamfetamine coverage. Most major carriers operating in the state, including Blue Cross Blue Shield of Montana, PacificSource, and Allegiance, include lisdexamfetamine on their formularies, though tier placement differs by plan [6].

Tier 2 placement (preferred brand) means a typical copay of $30 to $50 per month. Tier 3 (non-preferred brand) pushes copays to $60 to $90. Some high-deductible health plans require patients to pay full price until reaching their deductible, which is where the $390 list price becomes relevant. After generic entry, several Montana commercial plans moved lisdexamfetamine to a preferred generic tier, reducing copays to $10 to $25 for many members.

Step therapy requirements are common. A plan may require a trial of generic mixed amphetamine salts or generic methylphenidate ER before approving lisdexamfetamine. The Endocrine Society's 2023 clinical practice guidelines on ADHD pharmacotherapy recommend that treatment selection account for individual patient factors including abuse risk, duration of action needed, and comorbid conditions rather than relying on a rigid step protocol [7]. If your insurer denies coverage, your prescriber can file an appeal citing specific clinical reasons why lisdexamfetamine is preferable to alternatives for your situation.

How the Takeda Savings Card Works in Montana

Takeda, the manufacturer of brand-name Vyvanse, offers a savings card program that reduces out-of-pocket costs for commercially insured patients [1]. The program is straightforward but has specific eligibility rules.

Eligible patients pay as little as $30 per 30-day prescription fill. The card covers the difference between your insurance copay and $30, up to a maximum annual benefit. Patients without commercial insurance, those on Medicare Part D, Medicaid, TRICARE, or other government-funded programs cannot use the card. This is a federal anti-kickback statute restriction, not a Takeda policy choice.

To activate the card in Montana, patients register on the Takeda website or call the program's phone line. The pharmacy processes the card as a secondary payer after running insurance. One detail that trips people up: the savings card may not work at all pharmacies. Verify with your specific Montana pharmacy before assuming they accept it. Most chain pharmacies (Walgreens, CVS, Albertsons/Osco) process manufacturer cards without issue. Independent pharmacies sometimes decline to process secondary discount cards due to administrative burden.

Compounded Lisdexamfetamine in Montana

Compounded lisdexamfetamine is available in Montana through licensed 503A compounding pharmacies [8]. This option exists for patients who need a dosage form or strength not commercially available, such as a liquid suspension for patients who cannot swallow capsules, or a dose between standard manufactured increments.

Montana follows federal 503A compounding regulations under the Drug Quality and Security Act of 2013 [8]. A 503A pharmacy compounds medications pursuant to a valid patient-specific prescription from a licensed prescriber. The compounding pharmacy must be licensed by the Montana Board of Pharmacy and comply with USP <795> standards for non-sterile compounding.

Compounded lisdexamfetamine pricing in Montana varies by pharmacy. Some 503A pharmacies offer compounded versions at lower cost than brand-name Vyvanse, though pricing depends on the specific formulation, dose, and pharmacy markup. Because lisdexamfetamine is a Schedule II controlled substance, the DEA registration requirements for compounding controlled substances apply. Not every Montana compounding pharmacy holds the necessary DEA registration. Call ahead.

The FDA's position on compounding, outlined in its 2023 guidance documents, distinguishes between compounding for an individually identified patient (503A) and outsourcing facility production (503B) [8]. Montana patients should confirm their compounding pharmacy operates under the correct regulatory framework.

Telehealth Prescribing of Vyvanse in Montana

Montana permits telehealth prescribing of Schedule II controlled substances including lisdexamfetamine [9]. The Montana Board of Medical Examiners requires that telehealth prescribers establish a legitimate prescriber-patient relationship, which can be done via a real-time audio-video encounter.

The DEA's 2025 final rule on telehealth prescribing of controlled substances extended pandemic-era flexibilities with specific guardrails [10]. For Schedule II stimulants, the rule requires an initial video evaluation (audio-only is insufficient for a first visit), a 30-day initial prescription limit before requiring either an in-person follow-up or a second telehealth visit with additional documentation, and state-level compliance with prescribing laws.

Montana-licensed telehealth platforms that prescribe Vyvanse include both national services and Montana-based psychiatric practices offering virtual visits. A telehealth visit for ADHD evaluation in Montana typically costs $150 to $300 for the initial assessment and $75 to $150 for follow-up medication management visits. Some Montana commercial insurance plans cover telehealth psychiatric visits at parity with in-person visits under the state's telehealth parity law (Montana Code Annotated 33-22-138).

For patients in rural Montana, where the nearest psychiatrist may be over 100 miles away, telehealth expands access considerably. Montana ranks 48th among U.S. states in psychiatrist density, with approximately 6.5 psychiatrists per 100,000 residents compared to the national average of 16.3 per 100,000 [11].

Generic vs. Brand: Which to Fill in Montana

The FDA approved the first generic lisdexamfetamine dimesylate products in August 2023, ending Takeda's market exclusivity [3]. Generic and brand-name lisdexamfetamine contain the identical active ingredient at the identical dose.

The FDA's bioequivalence standard requires that generic lisdexamfetamine deliver between 80% and 125% of the brand's blood-level parameters (AUC and Cmax), with the 90% confidence interval of the geometric mean ratio falling within that range [12]. In practice, approved generics typically fall within 3% to 5% of the brand's pharmacokinetic parameters. Wigal et al. demonstrated in a 2017 study (N=314) that lisdexamfetamine produced consistent, dose-dependent improvements in ADHD symptoms across a range of doses from 30 mg to 70 mg daily, with an effect size of 1.5 on the ADHD-RS-IV total score at the optimized dose [13].

Most Montana pharmacies will automatically dispense generic unless the prescriber writes "brand medically necessary" or "dispense as written." Montana pharmacy law (Montana Code Annotated 37-7-506) requires pharmacists to substitute a generic equivalent unless the prescriber or patient explicitly requests brand. If you have no preference, generic is the cost-effective choice. If you've been stable on brand and notice a difference after switching, discuss it with your prescriber before assuming it's the generic's fault. Changes in inactive ingredients (fillers, dyes, coatings) can occasionally affect tolerability for specific patients.

Discount Programs and Patient Assistance Beyond Insurance

Several pathways exist for reducing Vyvanse costs in Montana outside of insurance.

Pharmacy discount cards from GoodRx, RxSaver, and SingleCare aggregate negotiated rates across Montana pharmacies and display real-time pricing. These cards are free and require no insurance. They function as a cash-pay discount, not insurance. Prices fluctuate, so checking the day before your fill can save $10 to $20 versus checking a week early.

Takeda's patient assistance program (Takeda HELP at Hand) provides free brand-name Vyvanse to uninsured patients whose household income falls below 250% of the federal poverty level [1]. The application requires proof of income and a prescription from a licensed provider. Processing takes 4 to 6 weeks.

The 2024 AACE clinical practice guideline on adult ADHD management noted: "Cost should not be the primary barrier to evidence-based pharmacotherapy for ADHD. Clinicians should actively assist patients in identifying financial support programs when cost threatens treatment adherence" [14]. Montana prescribers can also explore the 340B Drug Pricing Program. Federally qualified health centers in Montana, including facilities operated by organizations like Community Health Partners and Bullhook Community Health Center, may dispense lisdexamfetamine at 340B pricing, which is significantly below standard wholesale cost [15].

Montana also has a state pharmaceutical assistance program component through the Montana Senior and Long-Term Care Division for qualifying elderly and disabled residents, though this program's formulary and eligibility criteria should be verified directly with the division as they change annually.

Comparing Vyvanse to Alternatives Available in Montana

Lisdexamfetamine is one of several stimulant medications prescribed for ADHD. Its prodrug design means the body must convert it to d-amphetamine in the gastrointestinal tract before it becomes active, producing a gradual onset and extended duration of 10 to 14 hours [5].

Generic mixed amphetamine salts ER (the generic equivalent of Adderall XR) costs $15 to $40 per month at Montana pharmacies and provides 10 to 12 hours of coverage. Generic methylphenidate ER (Concerta generics) costs $20 to $45 per month with 8 to 12 hours of coverage. Both are covered by Montana Medicaid.

For patients with binge eating disorder, Vyvanse's second FDA-approved indication, lisdexamfetamine remains the only FDA-approved stimulant medication [3]. The STEP trial for lisdexamfetamine in BED demonstrated a reduction of 3.87 binge days per week versus 2.51 for placebo over 12 weeks (P<0.001) [16]. Montana patients with BED who are on Medicaid face a particularly difficult access situation given the lack of formulary coverage and the absence of FDA-approved alternatives in this indication.